The Peptide Hub
Evidence-first guides to the peptides people actually search for — organized by what they are used for, with FDA-approval status shown on every single one.
Educational only, not medical advice.
How to read the badges
FDA approved labeled drug, real trial program
Investigational in human trials, not yet approved
Research only little or no human efficacy data
We don’t treat “peptide” as one credibility bucket
Some peptides are FDA-approved medicines with large trial programs. Others are compounds with almost no human data that happen to be popular online. Those are completely different evidence situations, so every card below carries its own status. Browsing by class helps you find a compound; the badge tells you how much to trust what you read next.
Metabolic & GLP-1
Ozempic, Wegovy
GLP-1 receptor agonist with a large trial program and cardiovascular outcomes data.
Mounjaro, Zepbound
Dual GLP-1/GIP agonist approved for type 2 diabetes and chronic weight management.
“Triple G” agonist
GIP/GLP-1/glucagon agonist; five phase 3 trials reported, FDA filing planned Q1 2027; not approved.
EGRIFTA · narrow indication
GHRH analog approved specifically for HIV-associated lipodystrophy, not general fat loss.
Healing & recovery
Tissue, tendon, and gut repair. Heavily discussed in sport and recovery circles, but the human evidence is thin.
Growth hormone secretagogues
Compounds that nudge the body’s own growth-hormone axis. Published pharmacology, but none is an approved drug.
Selective ghrelin-receptor agonist
A selective GH secretagogue tested in people only by vein; its phase 2 trial failed and FDA advisers voted 0–12 against it in 2024.
Long-acting GHRH analog
Long-acting GHRH analog tested only in healthy adults; the no-DAC version sold in stacks has no published human study.
Cognitive & mood
Nootropic and anxiolytic peptides studied mainly in Russia; neither is FDA approved.
Longevity & skin
Anti-aging and cosmetic peptides. Interesting biology and big claims — the claims usually run well ahead of the human data.
Pineal tetrapeptide
Telomerase and lifespan claims come mainly from its developers’ group.
Calf-thymus polypeptide complex
Russian immune and aging studies; not FDA approved; distinct from thymogen (EW).
Mitochondrial-encoded peptide
Mouse metabolism and fitness data; no published study has given it to people.
FORZINITY · Barth syndrome only
Mitochondria-targeted peptide; approved for one ultra-rare disease, untested for aging.
Alpha-MSH tripeptide (Lys-Pro-Val)
Mouse colitis studies; no published human trial.
Copper tripeptide
Topical skin and wound research; injectable use is unproven.
More peptides: one evidence teardown each
Peptides that trend online but have no profile above yet. Each links to a sourced teardown of the trials, FDA status and safety reports. For a side-by-side view, see the FDA peptide status tracker.
Small-molecule “exercise pill,” not a peptide
Mice ran longer; no human trial; banned in sport from 2027.
Pig-brain peptide mixture used for stroke abroad
Largest stroke trial neutral; no effect on death; not approved in the US.
Oral ghrelin mimetic sold as a “growth hormone peptide”
Raised IGF-1 and lean mass, not strength or function; heart-failure signal; FDA category 2.
Growth hormone fragment, “fat-loss” peptide
Oral obesity trials in about 890 people failed; no published human trial of the injection.
Reproductive hormone peptide
Briefly raises LH and testosterone, but the effect fades with repeat use; FDA flags it as a safety risk.
Geref · discontinued 2008
Raised growth hormone in older adults, not strength or sleep; FDA withdrew its approvals in 2009.
Vyleesi · premenopausal women only
Modest benefit over placebo for low desire; never approved for men.
Tanning peptide
Darkens skin but is approved nowhere and gives no sun protection; tested products held 43% to 180% of label.
Delta sleep-inducing peptide
Small 1980s IV studies; independent trials found little benefit, and FDA advisers voted no.
Nootropic peptide
Never tested in a human trial; three related papers were retracted.
Mechano growth factor
Never tested in people; FDA has no human exposure data, and sport has banned it since 2005.
Human cathelicidin peptide
Its largest trial missed its goal; injected use is untested.
Zadaxin · immune peptide
FDA advisers voted 17-4 against compounding it; its largest trial found no survival benefit.
Coenzyme, not a peptide
No placebo-controlled trial has tested NAD+ drips or shots for aging.
Antioxidant tripeptide
FDA and CDC tied 2026 illnesses to supplement-grade powder; there is no FDA-approved glutathione product in the US.
What the evidence supports
- GLP-1 medicines (semaglutide, tirzepatide) have large randomized trials and labeled indications.
- Some secretagogues have real, published pharmacology even without an approved product.
- Approval status and evidence quality are not the same thing — we show both.
- Compounding or easy online availability does not equal FDA approval.
What we won’t fake certainty about
- Whether animal-only signals (BPC-157, TB-500) will hold up in humans.
- Whether single-group longevity claims (epitalon) replicate independently.
- Whether Russian-only studies (semax, selank, thymalin) replicate elsewhere.
- Long-term safety of research compounds used off-label without monitoring.
How to check any claim yourself
For approved drugs: Start with the FDA label, pivotal trial publications, and official safety communications.
For research compounds: Ask whether the literature is animal-only, uncontrolled, early-stage, or absent in humans.
For regulatory context
Use enforcement letters, shortage notices, and formal policy updates instead of vendor claims.
Educational content only. Nothing on this page is medical advice, and peptides described as “research only” are not approved by the FDA for human use. Talk to a qualified clinician before starting or changing any treatment.